logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Mitobridge, Inc.


USPTO Granted Patents = 20


Trademarks = 2

Forward Citations = 45

Loading Chart...
Loading Chart...

39 inventors (with patents filed for the assignee):

goldMedal Bharat Lagu (13 out of 25 patents)

silverMedal Arthur F Kluge (12 out of 96 patents)

bronzeMedal Michael Downes (8 out of 50 patents)

4.  Taisuke Takahashi (8 out of 10 patents)

5.  Ronald Mark Evans (8 out of 143 patents)

6.  Ramesh Senaiar (6 out of 6 patents)

7.  Sunil Kumar Panigrahi (6 out of 6 patents)

8.  Nan Ji (5 out of 54 patents)

9.  Masanori Miura (5 out of 20 patents)

10.  Susanta Samajdar (5 out of 5 patents)

11.  Michael A Patane (5 out of 52 patents)

12.  Scott Trzaska (3 out of 10 patents)

13.  Joseph Noel (3 out of 35 patents)

14.  Thomas J Baiga (3 out of 11 patents)

15.  John F W Keana (3 out of 28 patents)


20 patents:

1. 11993585 - Poly-ADP ribose polymerase (PARP) inhibitors (2024-05-28),
2. 11912681 - Crystalline and salt forms of PPAR agonist compounds (2024-02-27),
3. 11912679 - Aryl alkynamide derivatives (2024-02-27),
4. 11578052 - PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof (2023-02-14),
5. 11530192 - Crystalline and salt forms of PPAR agonist compounds (2022-12-20),
6. 11420934 - PPAR agonists (2022-08-23),
7. 11358954 - PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof (2022-06-14),
8. 11168080 - Dynamin-1-like protein inhibitors (2021-11-09),
9. 11034670 - Poly-ADP ribose polymerase (PARP) inhibitors (2021-06-15),
10. 10968172 - USP30 inhibitors (2021-04-06),
11. 10927094 - Crystalline and salt forms of PPAR agonist compounds (2021-02-23),
12. 10906885 - PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof (2021-02-02),
13. 10874641 - Methods of treating acute kidney injury (2020-12-29),
14. 10766888 - HMOX1 inducers (2020-09-08),
15. 10611790 - Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases (2020-04-07),
Company Overview
Mitobridge, Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies to enhance mitochondrial function. The organization specializes in research aimed at addressing various diseases linked to mitochondrial dysfunction, including metabolic and neurodegenerative disorders. By leveraging advanced scientific insights, Mitobridge seeks to create transformative treatments that improve patient outcomes and contribute to the understanding of mitochondrial biology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#137 in Cambridge, MA

#983 in Massachusetts

#16,382 in US

#31,233 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Mitobridge, Inc.

Forward Citations = 45

39 inventors:

goldMedal Bharat Lagu (13 out of 25 patents)

silverMedal Arthur F Kluge (12 out of 96 patents)

bronzeMedal Michael Downes (8 out of 50 patents)

4.  Taisuke Takahashi (8 out of 10 patents)

5.  Ronald Mark Evans (8 out of 143 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mitobridge, Inc.. Retrieved from https://idiyas.com/company/mitobridge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…